{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T18:23:40Z","timestamp":1744568620886},"reference-count":128,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1097\/crd.0000000000000035","type":"journal-article","created":{"date-parts":[[2014,8,6]],"date-time":"2014-08-06T11:03:10Z","timestamp":1407322990000},"page":"297-305","source":"Crossref","is-referenced-by-count":11,"title":["Existing Drugs and Agents Under Investigation for Pulmonary Arterial Hypertension"],"prefix":"10.1097","volume":"22","author":[{"given":"Mala","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sowmya","family":"Pinnamaneni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bartosz","family":"Jozwik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-6-20210203","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1161\/CIRCULATIONAHA.106.632208","article-title":"National Heart, Lung, and Blood Institute Working Group on Cellular and Molecular Mechanisms of Right Heart Failure. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure.","volume":"114","author":"Voelkel","year":"2006","journal-title":"Circulation"},{"key":"R4-6-20210203","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra035488","article-title":"Pulmonary arterial hypertension.","volume":"351","author":"Farber","year":"2004","journal-title":"N Engl J Med"},{"key":"R5-6-20210203","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1161\/CIRCULATIONAHA.106.674028","article-title":"Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications.","volume":"120","author":"Champion","year":"2009","journal-title":"Circulation"},{"key":"R6-6-20210203","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.","volume":"115","author":"DAlonzo","year":"1991","journal-title":"Ann Intern Med"},{"key":"R7-6-20210203","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1161\/CIRCULATIONAHA.109.192230","article-title":"ACCFAHA. ACCFAHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association.","volume":"119","author":"McLaughlin","year":"2009","journal-title":"Circulation"},{"key":"R8-6-20210203","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1378\/chest.14-0793","article-title":"Pharmacologic therapy for pulmonary arterial hypertension and adults. CHEST Guideline and Expert Panel Report.","volume":"146","author":"Taichman","year":"2014","journal-title":"Chest"},{"key":"R9-6-20210203","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/CRD.0b013e3181cd2c9e","article-title":"Pulmonary arterial hypertension: pathobiology, diagnosis, treatment and emerging therapies.","volume":"18","author":"Rosenbum","year":"2010","journal-title":"Cardiol in Rev"},{"key":"R10-6-20210203","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1056\/NEJMra050002","article-title":"Acute oxygen-sensing mechanisms.","volume":"353","author":"Weir","year":"2005","journal-title":"N Engl J Med"},{"issue":"suppl 5","key":"R11-6-20210203","doi-asserted-by":"crossref","first-page":"40S","DOI":"10.1378\/chest.83.5_Supplement.40S","article-title":"Pulmonary arterial wall injury and remodelling by hyperoxia.","volume":"83","author":"Jones","year":"1983","journal-title":"Chest"},{"key":"R12-6-20210203","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1073\/pnas.92.12.5510","article-title":"Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.","volume":"92","author":"Wang","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R13-6-20210203","doi-asserted-by":"crossref","first-page":"L296","DOI":"10.1152\/ajplung.00362.2002","article-title":"Hypoxia enhances a cGMP-independent nitric oxide relaxing mechanism in pulmonary arteries.","volume":"285","author":"Mingone","year":"2003","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"R15-6-20210203","doi-asserted-by":"crossref","first-page":"L334","DOI":"10.1152\/ajplung.00316.2010","article-title":"Sepiapterin improves angiogenesis of pulmonary artery endothelial cells with in utero pulmonary hypertension by recoupling endothelial nitric oxide synthase.","volume":"301","author":"Teng","year":"2011","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"R16-6-20210203","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1164\/rccm.200705-750OC","article-title":"Intrauterine pulmonary hypertension impairs angiogenesis in vitro: role of vascular endothelial growth factor nitric oxide signaling.","volume":"176","author":"Gien","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"R17-6-20210203","doi-asserted-by":"crossref","first-page":"L1111","DOI":"10.1152\/ajplung.00431.2005","article-title":"Nitric oxide augments fetal pulmonary artery endothelial cell angiogenesis in vitro.","volume":"290","author":"Balasubramaniam","year":"2006","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"R18-6-20210203","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1161\/01.CIR.102.22.2781","article-title":"Primary pulmonary hypertension: a vascular biology and translational research Work in progress.","volume":"102","author":"Archer","year":"2000","journal-title":"Circulation"},{"issue":"suppl 25","key":"R19-6-20210203","doi-asserted-by":"crossref","first-page":"D13","DOI":"10.1016\/j.jacc.2013.10.035","article-title":"Genetics and genomics of pulmonary arterial hypertension.","volume":"62","author":"Soubrier","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R20-6-20210203","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1161\/01.CIR.0000102381.57477.50","article-title":"Endothelial dysfunction in pulmonary hypertension.","volume":"109","author":"Budhiraja","year":"2004","journal-title":"Circulation"},{"key":"R21-6-20210203","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1096\/fj.00-0343com","article-title":"Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension.","volume":"15","author":"Taraseviciene-Stewart","year":"2001","journal-title":"FASEB J"},{"key":"R22-6-20210203","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.pharmthera.2013.10.002","article-title":"Targeted therapies in pulmonary arterial hypertension.","volume":"141","author":"Montani","year":"2014","journal-title":"Pharmacol Ther"},{"key":"R23-6-20210203","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0735-1097(02)01786-2","article-title":"Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomised, double-blind placebo-controlled trial.","volume":"39","author":"Galie","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R24-6-20210203","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0735-1097(03)00463-7","article-title":"Beraprost Study Group. Beraprost therapy for pulmonary arterial hypertension.","volume":"41","author":"Barst","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R25-6-20210203","doi-asserted-by":"crossref","first-page":"485","DOI":"10.7326\/0003-4819-112-7-485","article-title":"Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial.","volume":"112","author":"Rubin","year":"1990","journal-title":"Ann Intern Med"},{"key":"R26-6-20210203","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"key":"R27-6-20210203","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"key":"R28-6-20210203","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost in severe pulmonary hypertension.","volume":"347","author":"Olschewski","year":"2002","journal-title":"N Engl J Med"},{"key":"R29-6-20210203","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/hrt.80.2.151","article-title":"Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension.","volume":"80","author":"Higenbottam","year":"1998","journal-title":"Heart"},{"key":"R30-6-20210203","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. A double-blind, randomized, placebo-controlled trial.","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"R31-6-20210203","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.","volume":"55","author":"McLaughlin","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R33-6-20210203","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jacc.2005.04.050","article-title":"Ambrisentan therapy for pulmonary arterial hypertension.","volume":"46","author":"Galie","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R35-6-20210203","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet"},{"key":"R36-6-20210203","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension.","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"R37-6-20210203","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1183\/09031936.04.00028404","article-title":"Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.","volume":"24","author":"Humbert","year":"2004","journal-title":"Eur Respir J"},{"key":"R38-6-20210203","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(08)60919-8","article-title":"Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.","volume":"371","author":"Galie","year":"2008","journal-title":"Lancet"},{"key":"R39-6-20210203","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.106.630715","article-title":"Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study.","volume":"114","author":"Galie","year":"2006","journal-title":"Circulation"},{"key":"R40-6-20210203","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension.","volume":"369","author":"Pulido","year":"2013","journal-title":"N Engl J Med"},{"key":"R41-6-20210203","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension.","volume":"353","author":"Galie","year":"2005","journal-title":"N Engl J Med"},{"key":"R42-6-20210203","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jacc.2003.10.056","article-title":"Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study.","volume":"43","author":"Sastry","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"R43-6-20210203","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/eurheartj\/ehq011","article-title":"Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial.","volume":"31","author":"Iversen","year":"2010","journal-title":"Eur Heart J"},{"key":"R45-6-20210203","first-page":"2894","article-title":"Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension.","volume":"119","author":"Galie","year":"2009","journal-title":"Circulation"},{"key":"R46-6-20210203","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"PATENT-1 Study Group. Riociguat for the treatment of pulmonary arterial hypertension.","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"R47-6-20210203","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/263663a0","article-title":"An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation.","volume":"263","author":"Moncada","year":"1976","journal-title":"Nature"},{"key":"R48-6-20210203","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199207093270202","article-title":"An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension.","volume":"327","author":"Christman","year":"1992","journal-title":"N Engl J Med"},{"key":"R49-6-20210203","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1124\/jpet.107.124248","article-title":"2-4-(5,6-diphenylpyrazin-2-yl)(isopropyl)aminobutoxy-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug.","volume":"322","author":"Kuwano","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"R50-6-20210203","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/jpet.112.197152","article-title":"Differential effects of Selexipag corrected and prostacyclin analogs in rat pulmonary artery.","volume":"343","author":"Morrison","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"R51-6-20210203","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1183\/09031936.00137511","article-title":"Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension.","volume":"40","author":"Simonneau","year":"2012","journal-title":"Eur Respir J"},{"key":"R52-6-20210203","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1517\/14656566.2014.876007","article-title":"Selexipag for the treatment of pulmonary arterial hypertension.","volume":"15","author":"Skoro-Sajer","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"R53-6-20210203","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1161\/01.CIR.0000134595.80170.62","article-title":"Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential.","volume":"109","author":"Ichinose","year":"2004","journal-title":"Circulation"},{"key":"R54-6-20210203","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1161\/01.RES.76.2.215","article-title":"Continuous nitric oxide inhalation reduces pulmonary arterial structural changes, right ventricular hypertrophy, and growth retardation in the hypoxic newborn rat.","volume":"76","author":"Roberts","year":"1995","journal-title":"Circ Res"},{"key":"R55-6-20210203","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0002-9149(03)00910-X","article-title":"Acute hemodynamic effects and home therapy using a novel pulsed nasal nitric oxide delivery system in children and young adults with pulmonary hypertension.","volume":"92","author":"Ivy","year":"2003","journal-title":"Am J Cardiol"},{"key":"R56-6-20210203","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1378\/chest.109.6.1545","article-title":"Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests.","volume":"109","author":"Channick","year":"1996","journal-title":"Chest"},{"key":"R57-6-20210203","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/CRD.0b013e3181b3fe0d","article-title":"The emerging role of apelin in cardiovascular disease and health.","volume":"17","author":"Quazi","year":"2009","journal-title":"Cardiol Rev"},{"key":"R58-6-20210203","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1172\/JCI60658","article-title":"Molecular pathogenesis of pulmonary arterial hypertension.","volume":"122","author":"Rabinovitch","year":"2012","journal-title":"J Clin Invest"},{"key":"R59-6-20210203","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1172\/JCI43382","article-title":"Disruption of PPAR-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival.","volume":"121","author":"Alastalo","year":"2011","journal-title":"J Clin Invest"},{"key":"R60-6-20210203","first-page":"1","article-title":"Effect of apelin on vasodilatation of isolated pulmonary arteries in rats is concerned with the nitric oxide pathway.","volume":"27","author":"Huang","year":"2011","journal-title":"Zhongguo Ying Yong Sheng Li Xue Za Zhi"},{"key":"R61-6-20210203","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.peptides.2010.06.004","article-title":"Hemodynamic effect of apelin in a canine model of acute pulmonary thromboembolism.","volume":"31","author":"Feng","year":"2010","journal-title":"Peptides"},{"key":"R62-6-20210203","doi-asserted-by":"crossref","first-page":"H2007","DOI":"10.1152\/ajpheart.00089.2009","article-title":"Apelin decreases myocardial injury and improves right ventricular function in monocrotaline-induced pulmonary hypertension.","volume":"296","author":"Falcao-Pires","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R63-6-20210203","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2008.11.013","article-title":"2009 focused update incorporated into the ACCAHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology FoundationAmerican Heart Association Task Force on Practice Guidelines.","volume":"53","author":"Hunt","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R64-6-20210203","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1253\/circj.70.1208","article-title":"Upregulated neurohumoral factors are associated with left ventricular remodeling and poor prognosis in rats with monocrotaline-induced pulmonary arterial hypertension.","volume":"70","author":"Usui","year":"2006","journal-title":"Circ J"},{"key":"R65-6-20210203","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1164\/rccm.201003-0335OC","article-title":"Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats.","volume":"182","author":"Bogaard","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"R66-6-20210203","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1161\/CIRCHEARTFAILURE.111.964494","article-title":"Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension.","volume":"5","author":"de Man","year":"2012","journal-title":"Circ Heart Fail"},{"key":"R67-6-20210203","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.amjcard.2012.01.368","article-title":"Usefulness of beta-blocker therapy and outcomes in patients with pulmonary arterial hypertension.","volume":"109","author":"So","year":"2012","journal-title":"Am J Cardiol"},{"key":"R68-6-20210203","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.neuint.2004.03.016","article-title":"Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5).","volume":"45","author":"Corbin","year":"2004","journal-title":"Neurochem Int"},{"key":"R69-6-20210203","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1136\/hrt.2009.169417","article-title":"Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study.","volume":"95","author":"Jing","year":"2009","journal-title":"Heart"},{"key":"R70-6-20210203","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1164\/rccm.201101-0093OC","article-title":"Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension (EVALUATION) Study Group. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study.","volume":"183","author":"Jing","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"R71-6-20210203","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1161\/01.CIR.0000140724.90898.D3","article-title":"Increased sympathetic nerve activity in pulmonary artery hypertension.","volume":"110","author":"Velez-Roa","year":"2004","journal-title":"Circulation"},{"key":"R72-6-20210203","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1164\/rccm.200712-1876OC","article-title":"Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension.","volume":"177","author":"Forfia","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"R73-6-20210203","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1161\/CIRCULATIONAHA.112.094722","article-title":"Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension.","volume":"126","author":"Maron","year":"2012","journal-title":"Circulation"},{"key":"R74-6-20210203","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00109-010-0679-1","article-title":"Mitochondrial metabolic adaptation in right ventricular hypertrophy and failure.","volume":"88","author":"Piao","year":"2010","journal-title":"J Mol Med (Berl)"},{"key":"R75-6-20210203","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1164\/rccm.201108-1562OC","article-title":"Lung 18F-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring of pulmonary arterial hypertension.","volume":"185","author":"Marsboom","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"R76-6-20210203","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1161\/01.RES.0000145360.16770.9f","article-title":"Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis.","volume":"95","author":"McMurtry","year":"2004","journal-title":"Circ Res"},{"key":"R77-6-20210203","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1517\/13543781003727099","article-title":"New therapies for pulmonary arterial hypertension: an update on current bench to bedside translation.","volume":"19","author":"Dewachter","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"R78-6-20210203","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1006\/jmcc.1997.0461","article-title":"Cytoplasmic redox potential affects energetics and contractile reactivity of vascular smooth muscle.","volume":"29","author":"Barron","year":"1997","journal-title":"J Mol Cell Cardiol"},{"key":"R79-6-20210203","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0008-6363(96)00245-3","article-title":"Regulation of myocardial carbohydrate metabolism under normal and ischemic conditions. Potential for pharmacological interventions.","volume":"33","author":"Stanley","year":"1997","journal-title":"Cardiovasc Res"},{"issue":"suppl","key":"R80-6-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jcb.240550002","article-title":"Glucose fatty acid interactions and the regulation of glucose disposal.","volume":"55","author":"Randle","year":"1994","journal-title":"J Cell Biochem"},{"key":"R81-6-20210203","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00109-011-0804-9","article-title":"Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randles cycle.","volume":"90","author":"Fang","year":"2012","journal-title":"J Mol Med (Berl)"},{"key":"R82-6-20210203","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/01.CIR.93.1.135","article-title":"Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts.","volume":"93","author":"McCormack","year":"1996","journal-title":"Circulation"},{"key":"R83-6-20210203","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.jacc.2009.01.037","article-title":"Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial.","volume":"53","author":"Wilson","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R84-6-20210203","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4103\/2045-8932.109960","article-title":"Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension.","volume":"3","author":"Archer","year":"2013","journal-title":"Pulm Circ"},{"key":"R85-6-20210203","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/01.crd.0000138079.91392.37","article-title":"Rho-kinase inhibition in the therapy of cardiovascular disease.","volume":"13","author":"Lai","year":"2005","journal-title":"Cardiol Rev"},{"key":"R86-6-20210203","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1152\/japplphysiol.01318.2010","article-title":"Role of Rho-kinase signaling and endothelial dysfunction in modulating blood flow distribution in pulmonary hypertension.","volume":"110","author":"Schwenke","year":"2011","journal-title":"J Appl Physiol"},{"key":"R87-6-20210203","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1164\/rccm.200805-691OC","article-title":"RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling.","volume":"179","author":"Guilluy","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"R88-6-20210203","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/bjp.2008.239","article-title":"Therapeutic potential of RhoARho kinase inhibitors in pulmonary hypertension.","volume":"155","author":"Oka","year":"2008","journal-title":"Br J Pharmacol"},{"key":"R89-6-20210203","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1161\/01.RES.0000111804.34509.94","article-title":"Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats.","volume":"94","author":"Abe","year":"2004","journal-title":"Circ Res"},{"key":"R90-6-20210203","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1183\/09031936.00130209","article-title":"Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil.","volume":"36","author":"Mouchaers","year":"2010","journal-title":"Eur Respir J"},{"key":"R91-6-20210203","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/hrt.2003.029470","article-title":"Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension.","volume":"91","author":"Fukumoto","year":"2005","journal-title":"Heart"},{"key":"R92-6-20210203","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/157489011794578491","article-title":"Latest therapeutic novelties and patents in pulmonary hypertension.","volume":"6","author":"Hardavella","year":"2011","journal-title":"Recent Pat Cardiovasc Drug Discov"},{"key":"R93-6-20210203","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s00380-009-1176-8","article-title":"Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension.","volume":"25","author":"Fujita","year":"2010","journal-title":"Heart Vessels"},{"key":"R94-6-20210203","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1183\/09031936.00140309","article-title":"Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension.","volume":"36","author":"Dahal","year":"2010","journal-title":"Eur Respir J"},{"key":"R96-6-20210203","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0967-2109(01)00126-0","article-title":"The effects of vasoactive intestinal peptide on monocrotaline induced pulmonary hypertensive rabbits following cardiopulmonary bypass: a comparative study with isoproteronol and nitroglycerine.","volume":"10","author":"Gunaydin","year":"2002","journal-title":"Cardiovasc Surg"},{"key":"R97-6-20210203","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1172\/JCI17500","article-title":"Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension.","volume":"111","author":"Petkov","year":"2003","journal-title":"J Clin Invest"},{"key":"R98-6-20210203","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/1465-9921-12-141","article-title":"VIP and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension.","volume":"12","author":"Hamidi","year":"2011","journal-title":"Respir Res"},{"key":"R99-6-20210203","doi-asserted-by":"crossref","first-page":"L1013","DOI":"10.1152\/ajplung.00217.2009","article-title":"Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure.","volume":"297","author":"Stenmark","year":"2009","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"R100-6-20210203","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1161\/CIRCULATIONAHA.106.681718","article-title":"Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene.","volume":"115","author":"Said","year":"2007","journal-title":"Circulation"},{"key":"R101-6-20210203","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1183\/09031936.00050008","article-title":"Inhalation of vasoactive intestinal peptide in pulmonary hypertension.","volume":"32","author":"Leuchte","year":"2008","journal-title":"Eur Respir J"},{"key":"R103-6-20210203","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1164\/ajrccm.185.7.786","article-title":"Vasoactive intestinal peptide in pulmonary arterial hypertension.","volume":"185","author":"Said","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"R104-6-20210203","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1177\/0961203307087610","article-title":"Rituximab treatment of pulmonary arterial hypertension associated with systemic lupus erythematosus: a case report.","volume":"17","author":"Hennigan","year":"2008","journal-title":"Lupus"},{"key":"R105-6-20210203","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.pcad.2012.07.006","article-title":"Immune and inflammatory mechanisms in pulmonary arterial hypertension.","volume":"55","author":"El Chami","year":"2012","journal-title":"Prog Cardiovasc Dis"},{"key":"R106-6-20210203","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0002-9343(99)80156-9","article-title":"Increased plasma serotonin in primary pulmonary hypertension.","volume":"99","author":"Herve","year":"1995","journal-title":"Am J Med"},{"key":"R107-6-20210203","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/nm764","article-title":"Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension.","volume":"8","author":"Launay","year":"2002","journal-title":"Nat Med"},{"key":"R108-6-20210203","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1378\/chest.08-2823","article-title":"Selective serotonin reuptake inhibitors and the incidence and outcome of pulmonary hypertension.","volume":"136","author":"Shah","year":"2009","journal-title":"Chest"},{"key":"R109-6-20210203","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1183\/09031936.00126010","article-title":"Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats.","volume":"37","author":"Dumitrascu","year":"2011","journal-title":"Eur Respir J"},{"key":"R110-6-20210203","first-page":"A2496","article-title":"Proof-of-concept study to investigate the efficacy, hemodynamics and tolerability of terguride vs. placebo in subjects with pulmonary arterial hypertension: results of a double blind, randomised, prospective phase IIa study.","volume":"185","author":"Ghofrani","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"R111-6-20210203","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1161\/CIRCULATIONAHA.105.540542","article-title":"Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension.","volume":"112","author":"Merklinger","year":"2005","journal-title":"Circulation"},{"key":"R112-6-20210203","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1172\/JCI24838","article-title":"Reversal of experimental pulmonary hypertension by PDGF inhibition.","volume":"115","author":"Schermuly","year":"2005","journal-title":"J Clin Invest"},{"key":"R113-6-20210203","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1183\/09031936.98.11030554","article-title":"Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients.","volume":"11","author":"Humbert","year":"1998","journal-title":"Eur Respir J"},{"key":"R114-6-20210203","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1165\/ajrcmb.18.6.2980","article-title":"Increased vascular endothelial growth factor production in the lungs of rats with hypoxia-induced pulmonary hypertension.","volume":"18","author":"Christou","year":"1998","journal-title":"Am J Respir Cell Mol Biol"},{"key":"R115-6-20210203","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0955-0674(99)80028-3","article-title":"Organization and regulation of mitogen-activated protein kinase signaling pathways.","volume":"11","author":"Garrington","year":"1999","journal-title":"Curr Opin Cell Biol"},{"key":"R116-6-20210203","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1517\/13543784.2012.632408","article-title":"Imatinib mesylate for the treatment of pulmonary arterial hypertension.","volume":"21","author":"ten Freyhaus","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"R117-6-20210203","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/thx.2006.064097","article-title":"Long term imatinib treatment in pulmonary arterial hypertension.","volume":"61","author":"Souza","year":"2006","journal-title":"Thorax"},{"key":"R118-6-20210203","doi-asserted-by":"crossref","first-page":"152","DOI":"10.7326\/0003-4819-145-2-200607180-00020","article-title":"Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension.","volume":"145","author":"Patterson","year":"2006","journal-title":"Ann Intern Med"},{"key":"R119-6-20210203","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMc051946","article-title":"Imatinib for the treatment of pulmonary arterial hypertension.","volume":"353","author":"Ghofrani","year":"2005","journal-title":"N Engl J Med"},{"key":"R120-6-20210203","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1164\/rccm.201001-0123OC","article-title":"Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.","volume":"182","author":"Ghofrani","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"R121-6-20210203","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1161\/CIRCULATIONAHA.112.000765","article-title":"Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.","volume":"127","author":"Hoeper","year":"2013","journal-title":"Circulation"},{"key":"R122-6-20210203","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/clpt.2009.217","article-title":"A dosingcross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.","volume":"87","author":"Gomberg-Maitland","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"R123-6-20210203","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCULATIONAHA.108.776831","article-title":"Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics.","volume":"118","author":"Chen","year":"2008","journal-title":"Circulation"},{"key":"R124-6-20210203","first-page":"A6304","article-title":"Comparison of effects of imatinib and nilotinib in a rodent model of pulmonary arterial hypertension.","volume":"181","author":"Nicholas","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"R125-6-20210203","doi-asserted-by":"crossref","first-page":"720305","DOI":"10.1155\/2010\/720305","article-title":"Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension.","volume":"2010","author":"Furuya","year":"2010","journal-title":"Int J Rheumatol"},{"key":"R126-6-20210203","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1465-9921-8-15","article-title":"Rapamycin attenuates hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy in mice.","volume":"8","author":"Paddenberg","year":"2007","journal-title":"Respir Res"},{"key":"R127-6-20210203","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1126\/science.275.5302.964","article-title":"Isolation of putative progenitor endothelial cells for angiogenesis.","volume":"275","author":"Asahara","year":"1997","journal-title":"Science"},{"key":"R128-6-20210203","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1161\/CIRCULATIONAHA.108.769646","article-title":"Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension.","volume":"117","author":"Diller","year":"2008","journal-title":"Circulation"},{"key":"R129-6-20210203","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.rmed.2007.12.030","article-title":"Reduced number and activity of circulating endothelial progenitor cells in patients with idiopathic pulmonary arterial hypertension.","volume":"102","author":"Junhui","year":"2008","journal-title":"Respir Med"},{"key":"R130-6-20210203","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2353\/ajpath.2008.070705","article-title":"Circulating angiogenic precursors in idiopathic pulmonary arterial hypertension.","volume":"172","author":"Asosingh","year":"2008","journal-title":"Am J Pathol"},{"key":"R131-6-20210203","doi-asserted-by":"crossref","first-page":"33","DOI":"10.21693\/1933-088X-11.1.33","article-title":"Cell therapy for pulmonary arterial hypertension: potential efficacy of endothelial progenitor cells and mesenchymal stem cells.","volume":"11","author":"Suen","year":"2012","journal-title":"Adv Pulm Hyperten J"},{"key":"R132-6-20210203","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jacc.2006.12.037","article-title":"Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial.","volume":"49","author":"Wang","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R133-6-20210203","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1476-9255-2-8","article-title":"Mesenchymal stem cells avoid allogeneic rejection.","volume":"2","author":"Ryan","year":"2005","journal-title":"J Inflamm (Lond)"},{"key":"R134-6-20210203","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1002\/cphy.c120034","article-title":"Targeted delivery of genes to endothelial cells and cell- and gene-based therapy in pulmonary vascular diseases.","volume":"3","author":"Suen","year":"2013","journal-title":"Compr Physiol"},{"key":"R135-6-20210203","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1161\/01.RES.0000157672.70560.7b","article-title":"Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease.","volume":"96","author":"Zhao","year":"2005","journal-title":"Circ Res"},{"issue":"suppl 25","key":"R136-6-20210203","doi-asserted-by":"crossref","first-page":"D82","DOI":"10.1016\/j.jacc.2013.10.026","article-title":"New trial designs and potential therapies for pulmonary artery hypertension.","volume":"62","author":"Gomberg-Maitland","year":"2013","journal-title":"J Am Coll Cardiol"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T19:23:20Z","timestamp":1689449000000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045415-201411000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":128,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000035","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]}}}